Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.66 |
| ▸ | CTSS | P25774 | 2/20 | 0.66 |
| ▸ | CTSK | P43235 | 2/20 | 0.66 |
| ▸ | CTSB | P07858 | 1/20 | 0.66 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LAP3 | P28838 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17560 | 1.00 | CTSL (0.66) | CTSLCTSSCTSKCTSBCAPN1 | |
| SCHEMBL66243 | 1.00 | CTSL (0.66) | CTSLCTSSCTSKCTSBCAPN1 | |
| Fluoride SCHEMBL27561259 | 0.98 | CTSL (0.64) | CTSLCTSSCTSKCTSBCAPN1 | |
| Water SCHEMBL11331808 | 0.98 | CTSS (0.68) | CTSLCTSSCTSKCTSBCAPN1 | |
| Water SCHEMBL1069558 | 0.98 | CTSS (0.68) | CTSLCTSSCTSKCTSBCAPN1 | |
| Water SCHEMBL645995 | 0.98 | CTSS (0.68) | CTSLCTSSCTSKCTSBCAPN1 | |
| SCHEMBL28058660 | 0.98 | CTSL (0.64) | CTSLCTSSCTSKCTSBCAPN1 | |
| SCHEMBL8579795 | 0.98 | CTSL (0.64) | CTSLCTSSCTSKCTSBCAPN1 | |
| Water SCHEMBL2838131 | 0.98 | CTSS (0.68) | CTSLCTSSCTSKCTSBCAPN1 | |
| Hydrazine SCHEMBL8410651 | 0.97 | CTSL (0.62) | CTSLCTSSCTSKCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 793 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109867691-B | Aryl amine derivative and preparation method and application thereof | 广东工业大学 | 2021-11-30 | — | — | CN | claimed |
| CN-110343245-A | Glycopeptide of epsilon-polylysine-graft-hydrophobic amino acid-graft-trehalose and preparation method thereof | 天津大学 | 2019-10-18 | — | — | CN | claimed |
| US-10000520-B2 | B-vitamin and amino acid conjugates ofnicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof | ChromaDex Inc. (US) | 2018-06-19 | — | — | US | claimed |
| US-20170267709-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OFNICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | ChromaDex Inc. (US) | 2017-09-21 | — | — | US | claimed |
| CN-101245096-B | Liquid phase synthesizing method for N-benzyl oxylcarbonyl isoleucyl -beta-tert-butyl glutamyl-alanyl-amino aldehyde | SHANGHAI INST ORGANIC CHEM | 2010-12-15 | — | — | CN | claimed |
| EP-1194449-B1 | INHIBITORS OF MEMAPSIN 2 AND USE THEREOF | OKLAHOMA MED RES FOUND (US) | 2010-09-22 | — | — | EP | claimed |
| US-7678760-B2 | Inhibitors of Memapsin 2 and use thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-03-16 | — | — | US | claimed |
| CN-100590068-C | Method for preparing primary amine carbon nano tube | UNIV TONGJI | 2010-02-17 | — | — | CN | claimed |
| CN-101245096-A | Liquid phase synthesizing method for N-benzyl oxylcarbonyl isoleucyl -beta-tert-butyl glutamyl-alanyl-amino aldehyde | SHANGHAI INST ORGANIC CHEM (CN) | 2008-08-20 | — | — | CN | claimed |
| CN-101177259-A | Method for preparing primary amine carbon nano tube | UNIV TONGJI (CN) | 2008-05-14 | — | — | CN | claimed |
| US-7265140-B2 | Acyloxymethylcarbamate prodrugs of oxazolidinones | PFIZER INC (US) | 2007-09-04 | — | — | US | claimed |
| CN-1303086-C | Compound of dual functional esterified prodrug of Cefetamet, and oral preparation | ZHU XIAOMAO (CN) | 2007-03-07 | — | — | CN | claimed |
| EP-1668005-B1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | PHARMACIA & UPJOHN CO LLC (US) | 2007-02-14 | — | — | EP | claimed |
| EP-1668005-A1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | Pharmacia & Upjohn Company LLC (US) | 2006-06-14 | — | — | EP | claimed |
| US-20050267104-A1 | E.g., ({[Acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}-methyl)amino]carbonyl}oxymethyl acetate; these compounds have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria | PHARMACIA & UPJOHN COMPANY LLC | 2005-12-01 | — | — | US | claimed |
| CN-1687076-A | Compound of dual functional esterified prodrug of Cefetamet, and oral preparation | ZHU XIAOMAO (CN) | 2005-10-26 | — | — | CN | claimed |
| WO-2005028473-A1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-03-31 | — | — | WO | claimed |
| EP-0189803-B1 | INDOL-3-YL-QUINAZOLINO-1,4-BENZODIAZEPIN-5,13-DIONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1990-04-25 | — | — | EP | claimed |
| EP-0189803-A1 | Indol-3-yl-quinazolino-1,4-benzodiazepin-5,13-diones, process for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1986-08-06 | — | — | EP | claimed |
| US-4559339-A | CENTRAL NERVOUS SYSTEM, GASTROINTESTINAL DISORDERS | MERCK & CO., INC. (US) | 1985-12-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267104-A1 | E.g., ({[Acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}-methyl)amino]carbonyl}oxymethyl acetate; these compounds have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria | HDAC3, HDAC1, OGA | CTSL 1846/4885CTSS 3028/4885CTSK 1988/4885 |
| US-10000520-B2 | B-vitamin and amino acid conjugates ofnicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof | NAMPT, NAPRT, NNMT | CTSL 4053/4885CTSS 4478/4885CTSK 4555/4885 |
| US-20170267709-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OFNICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | NAMPT, NAPRT, NNMT | CTSL 4053/4885CTSS 4478/4885CTSK 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.